Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Nov 24, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating the combined use of Benzathine Penicillin and Etanercept for treating spondyloarthritis, which includes conditions like ankylosing spondylitis. The goal is to see if this combination can help reduce disease activity, improve symptoms, enhance daily functioning, and increase overall quality of life for patients with this condition. The study will compare this combination treatment to just continuing Etanercept alone.

To participate, individuals must be between 18 and 59 years old, have a confirmed diagnosis of spondyloarthritis, and be currently experiencing active symptoms of the disease. However, people with certain health issues, such as infections, severe heart problems, or those who are pregnant, will not be eligible. If you decide to participate, you can expect regular check-ins to monitor your health and any side effects from the medications. This trial is not yet recruiting participants, but it aims to provide valuable insights into new treatment options for managing spondyloarthritis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The following patients would be included: (1) The subjects voluntarily participate and sign an informed consent form; (2) patients aged 18-59 years; (3) According to the following guidelines or diagnostic criteria, a standardized diagnosis of spinal arthritis patients is made, which meets one of the following diagnostic criteria: ① 2009 ASAS classification criteria for axial spinal arthritis; ② Classification criteria for ASAS peripheral spondyloarthritis in 2011. And subjects with spinal arthritis who are in a relatively active period (ASDAS-CRP\>1.2 )of infection;
• Exclusion Criteria:
• • he exclusion criteria are as follows: (1) Subjects with nasopharyngitis, active tuberculosis, inflammatory bowel disease and other infections, other rheumatic and immune diseases, malignant tumors, and concomitant bone and joint diseases; (2) Individuals who are allergic to the components of the experimental drug; (3)Severe abnormalities in liver and kidney function (liver enzymes ≥ 2 times normal; creatinine ≥ 2 times normal); (4)Pregnant, preparing for pregnancy or breastfeeding women; (5)Moderate to severe heart failure (New York Heart Association grades 3-4); (6)Some researchers believe that other situations are not suitable for the use of etanercept or other experimental drugs; (7)Active gastrointestinal ulcer/bleeding; (8) According to the researcher's judgment, it is not suitable to participate in this study; (9)Patients in the acute phase of streptococcal infection: present with clinical manifestations of acute pharyngitis, acute tonsillitis, scarlet fever, and streptococcal pyoderma, and ASO or ADNS\>normal range, and/or CRP\>normal range.